Background & Aims: Tenofovir disoproxil fumarate (TDF) imposes a high genetic
Recently, Shirvani-Dastgerdi has identified an uncommon pattern of rtS78T/sC69* mutation in two TDF patients, which was associated with a 1.6-fold change in the half maximal effective concentration (EC50).(13) However, the presence of TDF resistant 5 mutants together with clinical viral breakthrough still turn into a rare event.
In the present study, we identified a quadruple HBV mutant (rtL180M/T184L/A200V/M204V) in a CHB patient with clinical viral rebound during TDF monotherapy. In vitro study indicated that this quadruple HBV mutant exhibited decreased sensitivity to TDF, with an approximate 4.5-fold higher EC50 than that of wild-type virus. Importantly this mutant was virologically suppressed by subsequent TDF/ETV combination rescue therapy. 
Patient and Methods

Patient
A 47-year-old woman who was diagnosed with CHB in 2001 and underwent NA treatment and serum levels of HBV DNA and ALT were periodically monitored. HBV DNA levels were monitored centrally with a Roche COBAS TaqMan HBV test(lower limit of quantification = 20 IU/mL). The HBV reverse transcriptase (RT) sequence was analyzed to identify potential drug resistance sites when virological breakthrough occurred. This study was approved by the Committee of Ethics at Beijing Ditan Hospital, Capital Medical University, and was conducted in accordance with the principles of the Declaration of Helsinki. All blood samples were collected after written informed consent was obtained. 
Statistical analysis
HBV replication intermediates were analyzed and quantified in Image Lab software.
Results are expressed as mean±standard deviation. EC50 was calculated through In 2013, given the increase in serum ALT level to 80 U/L, a sequencing analysis was performed, and an ETV-resistant triple-mutation of rtL180M/T184L/M204V was detected. In May 2014, the patient received TDF monotherapy (300 mg QD). Because of abnormal ALT level and detectable serum HBV DNA, TDF+ETV combination therapy was started in November 2014. During the subsequent 9 months' treatment, the viral load gradually decreased and eventually became undetectable (<20 IU/ml), and ALT was normalized.
In August 2016, ETV was tentatively discontinued, and TDF monotherapy continued.
Four months later, virological breakthrough occurred with an increased viral load (HBV DNA 10 7 IU/ml) and elevated ALT (80 U/L). An ETV/TDF regimen was resumed. After 8 months' treatment, the HBV viral load decreased to 1.16×10 3 IU/ml in Aug. 2017, and the ALT level returned to normal (Fig. 1) .
The patient was diagnosed with decompensate cirrhosis and experienced rupture of an rtA200V was detected ( Fig. 2A) . rtA200V was found only in four sequences among 8038 full-length HBV sequences in GenBank, indicating that rtA200V is a drug associated mutation rather than a polymorphic change. Other multi-drug resistance (MDR) mutations, including rtI169T, rtV173L, rtA181V/T, rtS202G/I, rtN236T and rtM250V, were not detected (Fig. 2B ).
Of note, as shown in Fig. 2A , the rtL180M/T184L/A200V/M204V quadruple mutant 
Viral replication competence and TDF sensitivity of rtA200V containing mutants
To further investigate TDF sensitivity of this quadruple mutant, we generated HBV constructs containing HBV mutants including rtL180M/M204V, rtL180M/T184L/M204V, rtA200V and rtL180M/A200V/T184L/M204V. These constructs were transiently transfected into HepG2 cells and HBV replicative intermediates were analyzed. In agreement with results from previous studies, both 1 2 rtL180M/T184L and rtL180M/T184L/M204V mutants showed lower replication competence (49.1% and 26.7%, respectively) than did the wild-type controls (Fig 3A   and 3B ). The replication competence of the rtA200V mutant and the rtL180M/A200V/T184L/M204V quadruple mutant was also attenuated (55.0% and 22.5% that of the wild-type, respectively; Fig 3A and 3B ). Because these mutations
were not located in the promoters of the HBV S and preC genes, no significant differences in the production of e and S antigens were observed (data not shown).
We treated the transfected HepG2 cells with a series of concentrations of TDF. HBV replication intermediate signals were collected, and the EC50 for TDF in each HBV mutant was determined by nonlinear regression with variable slope (Fig. 3C and 3D ).
In agreement with findings from previous reports, the rtL180M/T184L/M204V mutant was sensitive to TDF, with a 1.45-fold higher EC50 than that in the wild-type control (13.33 versus 9.17 nM), whereas the rtA200V mutant also displayed an EC50 comparable to that in wild type (1.28-fold, 11.70 nM). The EC50 of the rtL180M/T184L/A200V/M204V mutant was approximately 4.52 fold (41.42 nM) that in the wild-type control (Fig. 3D) . Therefore, the quadruple mutant rather than the rtL180M/T184L/M204V ETV-resistance mutation or rtA200V single mutation led to moderate resistance to TDF.
To further specify the mutations conferring decreased susceptibility to TDF, we constructed six additional combinations of mutants: rtL180M/A200V, rtT184L/A200V, rtA200V/M204V, rtL180M/T184L/A200V, rtT180/A200V/M204V and rtT184L/A200V/M204V. Southern blot assays revealed that all constructs displayed decreased intracellular HBV replicative intermediates (Fig S1) . All mutants expect 1 3 rtT184L/rtA200V/rtM204V were sensitive to TDF, and had comparable EC50 values for TDF (Fig. S2) . EC50 of rtT184L/rtA200V/rtM204V can not be determined because of the mutant's extremely low replication competence. The above results further indicated that the rtL180M/A200V/T184L/M204V quadruple mutant conferred decreased susceptibility to TDF.
Sensitivity of the quadruple mutant to ETV/TDF combination treatment
Because the clinical data indicated that the quadruple mutant was inhibited by ETV/TDF combination therapy, we next tested whether the quadruple mutant might be sensitive to ETV/TDF combination treatment in vitro. To this end, ETV and TDF were added into the medium at the EC50 (7.10 nM for ETV and 9.17 nM for TDF in our system) and with a 1.5-fold serial dilution. Both the wild type and the quadruple mutant were sensitive to ETV/TDF combination treatment (Fig. 4) , even at the low concentration of 0.3 fold of each EC50.
Spatial analysis of the quadruple mutant rtL180M/A200V/T184L/M204V
To illustrate the spatial position of the mutated rtA200V in HBV RT, we constructed a structural model of the HBV RT-DNA-tenofovir triphosphate complex with the PyMOL program. Previous studies have demonstrated that rtL180 and rtM204 are located near the catalytic and substrate binding center of RT, and their mutations affect the binding of substrates; rtT184 stabilizes the tyrosine-methionine-aspartate-aspartate (YMDD) loop, whereas rtT184L destabilizes the YMDD loop and thus hinders the binding of entecavir triphosphate (Fig. S3 ).
rtA200 is located in the middle of the RT C domain loop, and is far from the YMDD motif, thus indicating that rtA200V might not directly affect binding and catalysis of 1 4 substrates. Our study was limited to a single case of a patient with TDF resistance. However, potential cases with TDF-resistant mutants might be underestimated because TDF-resistant mutants might be suppressed by ETV/TDF combination therapy.
TDF-resistance associated mutation should be carefully investigated in patients with sequential NA treatment.
In summary, we report an rtL180M/T184S/A200V/M204V mutant that gained moderate resistance to TDF monotherapy in a stepwise manner. ETV/TDF combination therapy was found to be potently effective against this MDR HBV mutant. Southern blotting and quantitative analysis of wild type HBV (A) and HBV quadruple mutants (B). ETV and TDF were added to the medium at the EC50 (7.10 nM for ETV and 9.17 nM for TDF in our system) and with 1.5-fold serial dilution. 
